Antihypertensive Medications
Abstract
Concept set intended to identify patients with an exposure to an antihypertensive medication.
Affiliation(s)
Funder(s)
Provenance
Description
This medication concept set includes the following ingredients: ambrisentan, bethanidine, bosentan, cadralazine, clonidine, debrisoquin, deserpidine, diazoxide, dihydralazine, doxazosin, guanethidine, Guanoxan, hydralazine, indoramin, ketanserin, macitentan, mecamylamine, methoserpidine, methyldopa, metyrosine, minoxidil, moxonidine, nitroprusside, pargyline, pinacidil, prazosin, Rauwolfia preparation, rescinnamine, reserpine, rilmenidine, riociguat, Sitaxentan, tadalafil, Trimazosin, trimethaphan, urapidil, veratrum. It also includes combinations of these ingredients with other antihypertensive medications. This code list was generated by taking the descendants of all the ‘other’ antihypertensive ingredients of interest, and also doing string matching on the concept_name of the ingredient. This broad concept set was intended to identify patients who received ‘other’ antihypertensive ingredient not listed as RAAS blockers, calcium channel blockers, beta-blockers, or diuretics. Limited to RxNorm and RxNorm Extension codes.
Technical Note: This concept set was created when ingredients were required for some sites. It could be enhanced by using SCDF drug levels and taking descendants, which would also make this easier to refresh.
Development Code
Vocabulary
Clinical Subjects Headings
Related Publications
Stone HK, Mitsnefes M, Dickinson K, et al. 2023. “Clinical course and management of children with IgA vasculitis with nephritis.” Pediatr Nephrol 38, 3721�3733.
DOI: 10.1007/s00467-023-06023-8
Creative Commons license
